UT Colle

ge of M

edicine

Office o

f Contin

uing M

edical E

ducatio

n91

0 Madiso

n A

venue Suite

103

1Mem

phis, TN 381

63

The U

niversity

of T

ennessee is a

n EEO

/AA/Title V

I/Title

IX/S

ectio

n 504

/ADA/A

DEA

institu

tion in

the p

rovisio

n o

f its e

ducatio

n a

nd e

mploym

ent pro

gra

ms and services.

Non

-Pro

fit O

rg.

U S

POST

AGE

PAID

Mem

phis

, TN

Perm

it N

o. 1

180

2016 UTHSC Surgical OncologyAnnual Cancer Symposium:

An Update in the Multidisciplinary Care ofColorectal Cancer

OVERVIEW The University of Tennessee Health Science Center Division of SurgicalOncology is hosting a half-day symposium on colorectal cancer. Thesymposium will focus on key clinical topics in the management ofcolorectal cancer such as chemotherapy for early stage colon cancer,surgical approaches to rectal cancer, and management of liver andperitoneal metastases. It will also feature updates on current clinical trials incolorectal cancer. The symposium will provide a unique opportunity forclinicians involved in the care of cancer patients to learn from and interactwith leading national faculty in order to increase clinical knowledge, applynew data into practice, and ultimately improve patient outcomes.

LEARNING OBJECTIVES 1. To review evolving strategies in the management of patients with rectal

cancer with particular insights into the PROSPECT trial.

2. To review indications and ongoing investigations for consideration of adjuvant therapy in patients with early stage colon cancer.

3. To review the detection, appropriate surveillance, and management of polyposis syndromes and hereditary colon cancers.

4. To review contemporary surgical techniques for rectal cancer including indications and outcomes with minimally invasive total mesorectal excision and transanal endoscopic microsurgery.

5. To review implementation, importance, and implications of measuring and maintaining quality metrics in performance of colonoscopy.

6. To review surgical and nonsurgical liver directed therapy options for patients with colorectal liver metastases.

7. To review considerations and outcomes of performing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer.

TARGET AUDIENCE Surgical oncologists, general surgeons, medical oncologists, radiationoncologist, gastroenterologists, basic science researchers, primary careproviders

DISTINGUISHEDVISITINGPROFESSOR

Martin R. Weiser, MD is the incumbentof the Stuart H.Q. Quan Chair inColorectal Surgery and an AttendingSurgeon on the Colorectal Service atMemorial Sloan Kettering CancerCenter. He is Professor of Surgery atWeill Cornell Medical College. Dr.Weiser received his MD degree fromthe University Of Chicago PritzkerSchool Of Medicine and completedresidency at Brigham and Women’sHospital. He has completed

fellowships in surgical oncology and colorectal surgery. Dr. Weiserserves as Vice Chair for Education and Faculty Development in theDepartment of Surgery and has recently served as the Medical StaffPresident, Memorial Sloan Kettering Cancer Center. Dr. Weiser serveson the editorial board for the Journal of Clinical Oncology, Annals ofSurgical Oncology and the International Journal of Surgery. He is theColorectal Surgery section editor for Up-To-Date and the Annals ofSurgical Oncology. Dr. Weiser has been elected to the SouthernSurgical Association and the American Surgical Association. He is afellow of the American College of Surgeons, Society of SurgicalOncology and American Society of Colon and Rectal Surgeons.

Dr. Weiser’s research interests include modeling outcome andcolorectal cancer staging, tumor profiling, mechanisms of tumorresistance to receptor tyrosine kinases, multimodality treatment ofcolorectal cancer, minimally invasive and robotic surgery. He is thesurgical lead on the PROSPECT trial, a cooperative groupprospective randomized trial investigating neoadjuvant therapy forrectal cancer. He serves on the ASCRS Fundamentals of RectalCancer Surgery Committee, American Joint Committee on Cancer(AJCC) Colorectal Staging Taskforce (7th and 8th editions), and theAJCC Precision Medicine Committee. He is the past Chair of theColorectal Task Group for the Society of Surgical Oncology (SSO)and the Colorectal Track Leader for the Education Committee of theAmerican Society of Clinical Oncology (ASCO). Dr. Weiser hasmentored over 20 clinical and laboratory research fellows and haspublished over 170 peer review articles, 60 review articles, bookchapters, and editorials.

Colectoral Cancer Brochure_Brochure 5/31/16 8:38 AM Page 1

MEETING AGENDASaturday, September 17, 2016

7:30 - 8:00 Onsite Registration, Continental breakfast

8:00 - 8:05 Welcome and Opening RemarksMartin Fleming, MD, FACS, Chief of Surgical OncologyAssociate Professor of Surgery, Division of Surgical OncologyUniversity of Tennessee Health Science Center

8:05 - 8:45 Distinguished Visiting Professor Lecture -Evolving Treatment Paradigms for Rectal CancerMartin R. Weiser, MD, Stuart H.Q. QuanChair in Colorectal Surgery, Vice Chair for Education &Faculty Development, Department of Surgery Memorial Sloan Kettering Cancer Center

8:45 - 8:50 Q&A

8:50 - 9:15 Chemotherapy for Early Stage Colon Cancer –When and Why?Moon J Fenton, MD, PhD, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Tennessee Health Science Center, West Cancer Center

9:15 - 9:40 Hereditary Colon Cancer and Polyposis Syndromes Patrick M. Lynch, JD, MD, Professor, Departments of Gastroenterology, Hepatology, NutritionDivision of Internal MedicineThe University of Texas M.D., Anderson Cancer Center

9:40 - 9:50 Break

9:50 - 10:15 Surgical Approaches to Rectal Cancer –Options and OutcomesDavid Shibata, MD, FACS, FASCRSScheinberg Endowed Chair, Department of SurgeryUniversity of Tennessee Health Science Center

10:15 - 10:40 Quality Metrics for Colonoscopy Richard S. Aycock, MD, FACGClinical Assistant Professor of MedicineUniversity of Tennessee Health Science Center

10:40 - 10:50 Q&A

10:50 - 11:15 Treatment Strategies for Colorectal Liver Metastases Paxton V. Dickson, MD, FACS, Assistant Professor of Surgery Division of Surgical OncologyUniversity of Tennessee Health Science Center

11:15 - 11:40 Cytoreductive Surgery and HIPEC for Colorectal Peritoneal Metastases Jeremiah L. Deneve, DO, FACS, Assistant Professor of Surgery, Division of Surgical OncologyUniversity of Tennessee Health Science Center

11:40 - 12:10 Lunch/Break

12:10 - 1:00 Case Discussions with Multidisciplinary Panel/Faculty

1:00 - 1:15 Participant Evaluations

1:15 Adjourn

DISTINGUISHED LECTURERS

Richard S. Aycock, MD, FACG, earned his undergraduatedegree with honors from Texas A&M and his M.D. degreefrom the University of Texas Medical Branch in Galveston,Texas. He completed his internship, residency and fellowshipin Memphis at the University of Tennessee, Memphis. Dr.Aycock also completed a Research Fellowship inGastroenterology and Liver Disease and was an AmericanLiver Foundation Research Fellow. He is a Fellow of the

American College of Gastroenterology and a member of the AmericanCollege of Physicians, American Gastrointestinal Association, AmericanAssociation for the Study of Liver Disease and the Tennessee Society ofGastrointestinal Endoscopists. He is a former Assistant Professor of Medicine atthe University of Tennessee Memphis, The Health Science Center, and currentlyserves as Clinical Assistant Professor of Medicine at the University of Tennessee.While on faculty at the University of Tennessee, Dr. Aycock was the recipient ofa NIH Clinical Investigation Award as well as a VAMC Research AssociateAward. He is currently a Managing Partner of Gastro One in Memphis and thePresident of Tennessee Gastro, a statewide CIN (Clinically Integrated Network)based on quality metrics in gastroenterology.

Jeremiah L. Deneve, DO, FACS, is an Assistant Professor in theUniversity of Tennessee Health Science Center Departmentof Surgery, Division of Surgical Oncology. Dr. Denevecompleted his medical training at the Midwestern University,Chicago College of Osteopathic Medicine in Chicago,Illinois. He completed is residence in Surgery at EmoryUniversity School of Medicine in Atlanta Georgia. Dr. Deneveis board certified by the American Board of Surgery and has

special interests in the areas of: Esophageal and Gastric Malignancies,Hepatobiliary, Malignancies, Hyperthermic Intraperitoneal Chemotherapy(HIPEC), Pancreatic Malignancies, Cutaneous and Sarcoma Malignancies,and Regional Therapies for Peritoneal and Cutaneous Malignancies.

Paxton Dickson, MD, FACS is an Assistant Professor Surgery inthe University of Tennessee Health Science CenterDepartment of Surgery, Division of Surgical Oncology. Dr.Dickson joined the UTHSC faculty after completing surgicaloncology fellowship training at M.D. Anderson CancerCenter in Houston, Texas. His clinical practice is focusedprimarily on the multidisciplinary care of patients withhepatobiliary, pancreatic, and gastric malignancies as well

as the surgical treatment of endocrine disorders. Dr. Dickson has authoredseveral peer reviewed publications, reviews, and book chapters.

Moon J. Fenton, MD, PhD is is board-certified in InternalMedicine, Medical Oncology, and Hematology. She has awide interest, receiving her PhD studying cell signaltranduction pathyways in platelets and successfullypublishing several high-impact articles. Dr. Fenton receivedseveral pre-doctoral awards from the American Society ofHematology and the American Society of Cell Biology. Dr.Fenton also currently sits on the National Comprehensive

Care Network® (NCCN) panel for colorectal cancer, and is involved indevelopment of community-wide treatment pathways andrecommendations to treat colorectal cancers patients here in the Mid-South.

Patrick M. Lynch, JD, MD, is Professor in Department ofGastroenterology, Hepatology, and Nutrition at theUniversity of Texas MD Anderson Cancer Center. He haswritten extensively on the diagnosis and management ofinherited GI cancer syndromes. He has conducted anumber of clinical chemoprevention trials in FAP andHNPCC. An active member of the NCCN guidelinescommittee on high risk groups for colorectal cancer, he is

also a member of the NIH PDQ editorial board. Dr Lynch is past President ofthe International Society of Gastrointestinal Hereditary tumors (InSiGHT) and ofthe Collaborative Group of the Americas (CGA) on Inherited Colon Cancer.He is a current member of governing council of InSiGHT.

David Shibata, MD, FACS, FASCRS is the ScheinbergEndowed Chair of Surgery, Professor and Chairman of theDepartment of Surgery, Deputy Director of the UT WestCancer Center and Surgeon-in-Chief at the University ofTennessee Health Science Center in Memphis, TN.

Dr. Shibata attended medical school at McGill University inMontreal, Canada and received his General Surgery

training at the Beth Israel Deaconess Medical Center in Boston, MA. Hecompleted a Research Fellowship in Cancer Biology at Harvard MedicalSchool and a Surgical Oncology Fellowship at Memorial Sloan-KetteringCancer Center in New York, NY.

Dr. Shibata’s clinical practice is primarily dedicated to the treatment ofpatients with colorectal cancer. He is particularly interested in robotic andlaparoscopic minimally-invasive approaches to the treatment of colorectalcancer as well as sphincter-preserving techniques for patients with rectalcancer. He also has strong expertise in the management of high risk andhereditary colorectal cancer.

Dr. Shibata sits on the panel of the National Comprehensive CancerNetwork (NCCN) that establishes national guidelines for the treatment ofpatients with cancers of the colon, rectum and anus. He is also a memberof the Lower GI Cancer expert panel of the American Joint CancerCommission (AJCC) that establishes guidelines for the staging of colorectalcancer.

He is actively involved in colorectal cancer clinical research and clinicaltrials. Dr. Shibata's laboratory research is actively funded by the NationalCancer Institute and centers on the study of specific molecularmechanisms such as DNA methylation that contribute to the developmentof colorectal cancer.

PARKING Parking validation will be provided for participants parking for the plazaparking garage located off Madison Ave. connected to the Hamilton EyeInstitute.

REGISTRATION The registration fee is $50 for physicians (MD, DO, PhD) and $30 for physicianassistants and nurses (NP, RN). There is no charge for Residents or Fellows.Online registration available atwww.utconferences.com/cancersymposium2016.

CANCELLATION Full refunds will be given minus $15 administrative fee for cancellationnotices received in writing before September 9, 2016. UTHSC reserves theright to alter, reschedule, or cancel this program should circumstances sodictate.

ACCREDITATION The University of Tennessee College of Medicine is accredited by theAccreditation Council for Continuing Medical Education to providecontinuing medical education for physicians.

CREDIT The University of Tennessee College of Medicine designates this live activityfor a maximum of 4.5 AMA PRA Category 1 CreditsTM. Physicians shouldclaim only the credit commensurate with the extent of their participation inthe activity.

DISCLOSURE STATEMENT The University of Tennessee College of Medicine is committed to providingCME that is balanced, objective, and evidence-based. In accordance withthe Accreditation Council for Continuing Medical Education (ACCME)Essentials and Standards, all parties involved in content development arerequired to disclose any real or apparent conflicts of interest relating to thetopics of this educational activity. The University of Tennessee hasestablished mechanisms to resolve conflicts of interest should they arrive.Any potential conflict of interest or off label use will be disclosed to theaudience prior to the activity.

Colectoral Cancer Brochure_Brochure 5/31/16 8:39 AM Page 2